Abbott
ABT
Market cap $232B

135.62 USD

-0.83

0.61%

At close Jun 13, 4:00 PM EDT

After hours

136.37

+0.75

0.55%

1 day

-0.61%

5 days

1.95%

1 month

5.09%

3 months

4.41%

6 months

19.62%

Year to date

19.55%

1 year

31.10%

5 years

51.45%

10 years

182.13%

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees: 114,000

Healthcare Medical Devices

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

128% more first-time investments, than exits

New positions opened: 267 | Existing positions closed: 117

58% more funds holding in top 10

Funds holding in top 10: 72 [Q4 2024] → 114 (+42) [Q1 2025]

17% more call options, than puts

Call options by funds: $1.38B | Put options by funds: $1.18B

15% more capital invested

Capital invested by funds: $155B [Q4 2024] → $178B (+$23.2B) [Q1 2025]

3% more funds holding

Funds holding: 3,013 [Q4 2024] → 3,094 (+81) [Q1 2025]

0.05% less ownership

Funds ownership: 77.55% [Q4 2024] → 77.5% (-0.05%) [Q1 2025]

15% less repeat investments, than reductions

Existing positions increased: 1,118 | Existing positions reduced: 1,315

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$127

6%

downside

Avg. target

$143

6%

upside

High target

$159

17%

upside

8 analyst ratings

6 positive

75%

2 neutral

25%

0 negative

0%

Raymond James Jayson Bedford	5%upside $142	Outperform Maintained	17 Apr 2025
Piper Sandler Adam Maeder	7%upside $145	Overweight Reiterated	17 Apr 2025
RBC Capital Shagun Singh	7%upside $145	Outperform Maintained	17 Apr 2025
Wells Fargo Lawrence Biegelsen	8%upside $147	Overweight Maintained	17 Apr 2025
Morgan Stanley David Lewis	6%downside $127	Equal-Weight Maintained	17 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 25 articles about ABT published over the past 30 days

Abbott Declares 406th Consecutive Quarterly Dividend

ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.

Abbott Declares 406th Consecutive Quarterly Dividend

24/7 Wall Street

5 Dividend Kings Are Delivering Massive Total Returns of Up to 34% This Year

Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.

5 Dividend Kings Are Delivering Massive Total Returns of Up to 34% This Year

The Motley Fool

5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off

Volatility is a part of life for long-term investors. The reasons the market goes up or down change, but the constant is that high-quality stocks, businesses that increasingly make more money over time, will reward investors if you wait long enough.

5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off

Zacks Investment Research

NVST vs. ABT: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Products sector have probably already heard of Envista (NVST) and Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?

NVST vs. ABT: Which Stock Should Value Investors Buy Now?

The Highest-Quality Dividend Contenders By Quality Scores

The article presents the highest-quality Dividend Contenders, companies listed on U.S. exchanges with higher annual dividend payouts for 10-24 consecutive years. I use a quality scoring system with six quality indicators, each worth five points, for a maximum score of 30. The highest-quality Dividend Contenders score four or five points for each quality indicator.

The Highest-Quality Dividend Contenders By Quality Scores

Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?

The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.

Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?

Zacks Investment Research

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

Zacks Investment Research

Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note

Abbott (ABT) closed at $132.96 in the latest trading session, marking a -0.56% move from the prior day.

Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note

Zacks Investment Research

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds

ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.

Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds

See News Rankings

Charts implemented using Lightweight Charts™